Skip to main content
SpringerLink
Log in

Functional Imaging-Guided Radiotherapy and Radiolabelled Targeted Therapies in Prostate Cancer

  • Chapter
  • First Online:
Principles and Practice of Urooncology

  • 1094 Accesses

Abstract

Positron emission tomography (PET) imaging using PSMA ligand is a promising radiotracer in prostate cancer. Recent trials suggest its potential role in accurate staging of high-risk prostate cancer and detecting metastases and local-regional relapses during biochemical recurrence with 68Ga-PSMA positron emission tomography/computed tomography (PET/CT). However, the data related with its role in radiotherapy are still lacking. Therefore, we summarized our experience with 68Ga-PSMA PET/CT guided hypofractionated stereotactic radiotherapy in patients with oligometastatic disease after biochemical recurrence. Radiolabelled targeted therapies gains popularity in the management metastatic bone disease in prostate cancer. We particularly review the applications of radium-223 chloride in prostate cancer patients in the light of available clinically relevant data.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20.

    Article  CAS  PubMed  Google Scholar 

  2. Schmid DT, John H, Zweifel R, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology. 2005;235(2):623–8.

    Article  PubMed  Google Scholar 

  3. Krause BJ, Souvatzoglou M, Tuncel M, et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35(1):18–23.

    Article  CAS  PubMed  Google Scholar 

  4. Castellucci P, Picchio M. 11C-choline PET/CT and PSA kinetics. Eur J Nucl Med Mol Imaging. 2013;40(Suppl 1):S36–40.

    Article  PubMed  Google Scholar 

  5. Beer AJ, Eiber M, Souvatzoglou M, et al. Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol. 2011;12(2):181–91.

    Article  PubMed  Google Scholar 

  6. Eiber M, Weirich G, Holzapfel K, et al. Simultaneous 68Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer. Eur Urol. 2016;70(5):829–36.

    Article  CAS  PubMed  Google Scholar 

  7. Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic efficacy of (68)gallium-PSMA positron emission tomography compared to conventional imaging in lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 2016;195(5):1436–43.

    Article  PubMed  Google Scholar 

  8. Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56(5):668–74.

    Article  PubMed  Google Scholar 

  9. Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197–209.

    Article  CAS  PubMed  Google Scholar 

  10. Maurer T, Weirich G, Schottelius M, et al. Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. Eur Urol. 2015;68(3):530–4.

    Article  PubMed  Google Scholar 

  11. Artigas C, Alexiou J, Garcia C, et al. Paget bone disease demonstrated on (68)Ga-PSMA ligand PET/CT. Eur J Nucl Med Mol Imaging. 2016;43(1):195–6.

    Article  CAS  PubMed  Google Scholar 

  12. Kanthan GL, Drummond J, Schembri GP, et al. Follicular thyroid adenoma showing avid uptake on 68Ga PSMA-HBED-CC PET/CT. Clin Nucl Med. 2016;41(4):331–2.

    Article  PubMed  Google Scholar 

  13. Kobe C, Maintz D, Fischer T, et al. Prostate-specific membrane antigen PET/CT in splenic sarcoidosis. Clin Nucl Med. 2015;40(11):897–8.

    Article  PubMed  Google Scholar 

  14. Rischpler C, Maurer T, Schwaiger M, et al. Intense PSMA-expression using (68)Ga-PSMA PET/CT in a paravertebral schwannoma mimicking prostate cancer metastasis. Eur J Nucl Med Mol Imaging. 2016;43(1):193–4.

    Article  PubMed  Google Scholar 

  15. Krohn T, Verburg FA, Pufe T, et al. [(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging. 2015;42(2):210–4.

    Article  PubMed  Google Scholar 

  16. Schwenck J, Tabatabai G, Skardelly M, et al. vivo visualization of prostate-specific membrane antigen in glioblastoma. Eur J Nucl Med Mol Imaging. 2015;42(1):170–1.

    Article  PubMed  Google Scholar 

  17. Verburg FA, Krohn T, Heinzel A, et al. First evidence of PSMA expression in differentiated thyroid cancer using [68Ga]PSMA-HBED-CC PET/CT. Eur J Nucl Med Mol Imaging. 2015;42(10):1622–3.

    Article  PubMed  Google Scholar 

  18. Rowe SP, Gorin MA, Hammers HJ, et al. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted (18)F-DCFPyL PET/CT. Ann Nucl Med. 2015;29(10):877–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Pyka T, Weirich G, Einspieler I, et al. 68Ga-PSMA-HBED-CC PET for differential diagnosis of suspicious lung lesions in patients with prostate cancer. J Nucl Med. 2016;57(3):367–71.

    Article  PubMed  Google Scholar 

  20. Sasikumar A, Joy A, Nanabala R, et al. (68)Ga-PSMA PET/CT imaging in primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2016;43(4):795–6.

    Article  PubMed  Google Scholar 

  21. Kluetz PG, Pierce W, Maher VE, Zhang H, Tang S, Song P, Liu Q, Haber MT, Leutzinger EE, Al-Hakim A, Chen W, Palmby T, Alebachew E, Sridhara R, Ibrahim A, Justice R, Pazdur R. Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res. 2014 Jan 1;20(1):9–14. doi:10.1158/1078-0432.CCR-13-2665. PMID: 24190979. Free Article.

  22. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall’Oglio M, Franzén L, Coleman R, Vogelzang NJ, O’Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O, ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013 Jul 18;369(3):213–23. doi:10.1056/NEJMoa1213755. PMID: 23863050.

  23. Parker CC, Pascoe S, Chodacki A, O’Sullivan JM, Germá JR, O’Bryan-Tear CG, Haider T, Hoskin P. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol. 2013 Feb;63(2):189–97. doi:10.1016/j.eururo.2012.09.008. PMID: 23000088.

  24. Hoskin P, Sartor O, O’Sullivan JM, Johannessen DC, Helle SI, Logue J, Bottomley D, Nilsson S, Vogelzang NJ, Fang F, Wahba M, Aksnes AK, Parker C. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014 Nov;15(12):1397–406. doi:10.1016/S1470-2045(14)70474-7. PMID: 25439694.

  25. Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Vogelzang NJ, O’Bryan-Tear CG, Shan M, Bruland ØS, Parker C. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014 Jun;15(7):738–46. doi:10.1016/S1470-2045(14)70183-4. PMID: 24836273.

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Hacettepe University, Ankara, Turkey

    Gokhan Ozyigit M.D., Sezin Yuce Sari M.D. & Pervin Hurmuz M.D.

  2. Department of Radiation Oncology, Koc University, Istanbul, Turkey

    Ugur Selek M.D.

Authors
  1. Gokhan Ozyigit M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sezin Yuce Sari M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pervin Hurmuz M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ugur Selek M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gokhan Ozyigit M.D. .

Editor information

Editors and Affiliations

  1. Chair and Professor, Department of Radiation Oncology, Hacettepe University, Ankara, Turkey

    Gokhan Ozyigit

  2. Chair and Professor, Department of Radiation Oncology, Koc University, Istanbul, Turkey

    Ugur Selek

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Ozyigit, G., Sari, S.Y., Hurmuz, P., Selek, U. (2017). Functional Imaging-Guided Radiotherapy and Radiolabelled Targeted Therapies in Prostate Cancer. In: Ozyigit, G., Selek, U. (eds) Principles and Practice of Urooncology. Springer, Cham. https://doi.org/10.1007/978-3-319-56114-1_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56114-1_25

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56113-4

  • Online ISBN: 978-3-319-56114-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation